ADMA Q3 Revenue $141.1M, EPS $0.22; FY26 Revenue Guidance Reiterated, Earnings Outlook Raised
ADMA sits 94% above its 52-week low of $7.21 on elevated volume (4.5× avg).
Summary
ADMA reported Q3 2026 revenue of $141.1M (up 5%) and GAAP EPS of $0.22 (up 47%), with ASCENIV up 31% offsetting a 35% BIVIGAM decline. Full-year revenue guidance was reiterated at $530M+ while the Adjusted EBITDA floor was raised to $275M+.
Key Events · Earnings and Guidance · ADMA
-
Q3 Revenue $141.1M, EPS $0.22
Total revenue rose 5% year-over-year to $141.1M and 13% sequentially; GAAP net income was $49.9M and basic EPS $0.22, up 47% from $0.15.
-
ASCENIV Up 31%, BIVIGAM Down 35%
ASCENIV revenue reached $124.7M (+31% year-over-year, +21% sequentially) while BIVIGAM fell to $15.4M from $23.8M on competitive pricing and channel inventory pressure.
-
FY26 Earnings Outlook Raised
Revenue guidance reiterated at at least $530M; Adjusted Net Income floor raised to at least $180M and Adjusted EBITDA to at least $275M.
-
SG-001 FDA Feedback Constructive
FDA feedback on the pre-IND package supports the proposed clinical strategy and assay; ADMA plans to finalize the protocol and prepare an IND submission. Management sizes the opportunity at $300-500M in annual revenue if approved.
Analysis · ADMA · Life Sciences
The quarter itself is strong: ASCENIV revenue rose 31% to $124.7M and gross margin expanded to 71% from 56%, pushing GAAP net income up 37% to $49.9M. The more consequential item is the outlook — management reiterated at least $530M of FY2026 revenue but raised the floor on Adjusted Net Income to at least $180M and Adjusted EBITDA to at least $275M, which implies the margin story is running ahead of prior expectations. Offsetting that, BIVIGAM fell 35% year-over-year to $15.4M on competitive pricing in the standard IG market, so total revenue growth was only 5%. The company also disclosed constructive FDA feedback on its SG-001 pre-IND package, with an IND submission planned next — a $300-500M annual revenue opportunity if approved, but still preclinical. Buybacks remain aggressive: 16.5M shares repurchased year-to-date for $180.3M, with the $200M 2026 target on track.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADMA was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.21 to $20.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.